塞托雷生单药治疗重性抑郁障碍的疗效与安全性:一项随机安慰剂对照临床试验
该随机、双盲、安慰剂导入、1b期研究纳入128例重性抑郁障碍患者,其中86例为导入期安慰剂无应答者(富集意向性治疗集)。第5周HDRS17评分较基线平均变化在20 mg组、40 mg组与安慰剂组间差异有统计学意义(p=0.0456),归因于20 mg组与安慰剂组的差异(p=0.0049)。
要点
- 第5周HDRS17平均变化:塞托雷生20 mg组-7.0、40 mg组-5.5、安慰剂组-4.4(p=0.0456)。
- 20 mg组与安慰剂组差异有统计学意义(p=0.0049),40 mg组与安慰剂组未见对应报告。
- 基线失眠越重者,20 mg组第5周抑郁严重度改善越明显(名义p=0.0059)。
核心结论
- 在富集意向性治疗集中,第5周HDRS17评分较基线平均变化在20 mg组、40 mg组与安慰剂组间差异有统计学意义(p=0.0456),归因于20 mg组与安慰剂组的差异(p=0.0049)。
研究设计与样本
- 安慰剂对照、安慰剂导入、随机、双盲、1b期研究,受试者随机接受塞托雷生20 mg、40 mg或安慰剂。
- 共纳入128例受试者,其中富集样本(导入期安慰剂无应答者)86例。
- 主要疗效分析为富集意向性治疗集,评估从治疗期基线至第5周HDRS17评分变化。
主要发现
- 第5周HDRS17评分较基线平均变化(标准差):20 mg组-7.0(5.04)、40 mg组-5.5(4.34)、安慰剂组-4.4(3.67),组间差异p=0.0456。
- 20 mg组与安慰剂组差异有统计学意义(p=0.0049)。
- 基线失眠严重度越高的患者,20 mg组第5周抑郁严重度改善越明显(名义p=0.0059)。
- 去除HDRS睡眠条目后校正评分,20 mg组疗效获益仍有统计学意义(名义p=0.0289)。
- 20 mg组较安慰剂组的HDRS17平均变化在数值上大于40 mg组,与既往塞托雷生联合常规抗抑郁药研究数据一致。
关键数值与推荐
- 次要分析中,觉醒皮质醇反应在20 mg组降低,而40 mg组和安慰剂组未见降低。
- 总睡眠时间在40 mg组增加更多,但该组同时出现REM入睡潜伏期缩短和N1期睡眠增加,20 mg组未见这些变化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The antidepressant efficacy and safety of seltorexant monotherapy in major depressive disorder (MDD) was investigated in a placebo-controlled, placebo lead-in, randomized, double-blind, phase 1b study. Participants were randomized to receive seltorexant (20 mg or 40 mg) or placebo. The treatment effect was assessed by changes in the Hamilton Rating Scale for Depression-17 item (HDRS17) from treatment-period baseline to week 5 in lead-in placebo non-responders ("enriched" intent-to-treat analysis set). As a secondary outcome, the effect of seltorexant on HDRS17 was assessed in patients with and without subjective insomnia. Seltorexant's effects on polysomnography, serum cortisol, and cortisol waking response were also measured. In total, 128 participants were enrolled, including 86 in the enriched sample (lead-in placebo non-responders). The mean changes from baseline (SD) in HDRS17 score at week 5 differed significantly across arms: -7.0 (5.04) for seltorexant 20 mg, -5.5 (4.34) for seltorexant 40 mg, and -4.4 (3.67) for placebo (p = 0.0456), which was attributable to the difference between the 20 mg and placebo arms (p = 0.0049). Improvement in depression severity at week 5 for seltorexant 20 mg was greater in patients with higher baseline insomnia severity (nominal p = 0.0059). The treatment benefit in the 20 mg arm remained significant when HDRS scores were adjusted by removing the sleep items (nominal p = 0.0289). The mean HDRS17 change versus placebo was numerically larger in the 20 mg than the 40 mg arm, consistent with data from a previous study in which seltorexant was administered adjunctively to conventional antidepressants. In secondary analyses, the waking cortisol response decreased in the 20 mg arm but not the 40 mg or placebo arms, and while total sleep increased more in the 40 mg arm, this arm also showed reduced REM onset latency and increased stage N1 sleep, which were not evident in the 20 mg arm. These biomarker data suggest mechanistic hypotheses that may account for the apparent curvilinear dose-response relationship of seltorexant. Trial Registration: ClinicalTrials.gov, NCT03374475.
引用
- Mesens S, Kezic I, Van Der Ark P, et al. Treatment effect and safety of seltorexant as monotherapy for patients with major depressive disorder: a randomized, placebo-controlled clinical trial. Mol Psychiatry. 2024. PMID: 39663378. doi:10.1038/s41380-024-02846-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。